Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867684 | 0.83 | ALOX5 (0.43) | MAPTSMN1; SMN2TP53LMNAADRB1 | |
| SCHEMBL6869847 | 0.82 | MAPT (0.44) | GFERTSHRMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL6865906 | 0.82 | MAPK1 (0.44) | TSHRMAPTNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1899257 | 0.80 | MAPT (0.44) | GFERMAPTNPSR1SMN1; SMN2TP53 | |
| SCHEMBL8407231 | 0.77 | CA1 (0.45) | LMNA | |
| SCHEMBL654651 | 0.76 | ADRB1 (0.62) | TSHRMAPTNPSR1ADRB1ALDH1A1 | |
| SCHEMBL13060129 | 0.76 | KMT2A (0.54) | GFERTSHRMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL16378121 | 0.76 | KMT2A (0.54) | GFERTSHRMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL8053460 | 0.74 | GFER (0.53) | GFERTSHRMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL12658289 | 0.73 | GFER (0.55) | GFERTSHRMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE HOLDINGS CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9801877-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2017-02-09 | — | — | US | disclosed |
| EP-3020402-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Holdings Corporation (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-1622569-B1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-8637497-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2617419-A1 | Aza spiro alkane derivatives as inhibitors of metallproteases | Incyte Corporation (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION | 2011-11-24 | — | — | US | disclosed |
| EP-1091957-A1 | PYRIMIDIN-AMINOMETHYL-PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE CONTROL OF HELICOBACTER BACTERIA | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-04-18 | — | — | EP | disclosed |
| EP-1086094-A1 | QUINOLINE-AMINOMETHYL-PYRIDYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-03-28 | — | — | EP | disclosed |
| US-6162809-A | Pyridylthio compounds for controlling helicobacter bacteria | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-12-19 | — | — | US | disclosed |
| WO-1999061439-A1 | PYRIMIDIN-AMINOMETHYL-PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE CONTROL OF HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999061438-A1 | QUINOLINE-AMINOMETHYL-PYRIDYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-12-02 | — | — | WO | disclosed |
| US-5925642-A | ANTITUMOR, ANTIMETASTASIS AGENTS; DRUG RESISTANCE MODULATORS; SYNERGISTIC MIXTURES WITH ANTIBIOTICS AND CYTOSTATIC AGENTS; SIDE EFFECT REDUCTION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-07-20 | — | — | US | disclosed |
| US-5668131-A | CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-16 | — | — | US | disclosed |
| EP-0740649-A1 | NITROXY GROUP-CONTAINING BENZYLAMINE DERIVATIVES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES, AS WELL AS INCREASED INTRA-OCULAR PRESSURE | Byk Nederland BV (NL) | 1996-11-06 | — | — | EP | disclosed |
| WO-1996000224-A1 | 4-S- AND N-SUBSTITUTED 6-ALKYLPYRIDINES FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-01-04 | — | — | WO | disclosed |
| WO-1995019952-A1 | NITROXY GROUP-CONTAINING BENZYLAMINE DERIVATIVES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES, AS WELL AS INCREASED INTRA-OCULAR PRESSURE | BYK NEDERLAND BV (NL) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | GFER 1353/4885TSHR 3553/4885MAPT 4566/4885 |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | MMP9, MMP3, MMP12 | GFER 1353/4885TSHR 3553/4885MAPT 4566/4885 |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | GFER 1353/4885TSHR 3553/4885MAPT 4566/4885 |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | GFER 1353/4885TSHR 3553/4885MAPT 4566/4885 |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | GFER 1353/4885TSHR 3553/4885MAPT 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.